TD Securities upgraded Valeant Pharmaceuticals (NYSE: VRX) from Hold to Buy with a price target of $160.00 (from $145.00). The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE